2025-04-23T08:33:47-05:00 2024-06-30 BDO USA 200 PARK AVENUE 38TH FLOOR NEW YORK NY 10166 990 2023-07-01 954335088 Lymphoma Research Foundation % THE ORGANIZATION LYMP 2123492910 WALL ST PLAZA 88 PINE ST STE 2400 NEW YORK NY 10005 HILLEL HYMAN AUTHORIZED SIGNOR 2123492910 2025-04-21 true true Paul Hammerschmidt P01384178 2128858000 2025-04-20 2023 2025-03-06 01:10:19Z HILLEL HYMAN WALL ST PLAZA 88 PINE ST STE 2400 NEW YORK NY 10005 130404027 false X WWW.LYMPHOMA.ORG X 1991 CA TO ERADICATE LYMPHOMA AND SERVE THOSE TOUCHED BY THIS DISEASE. 18 18 36 20000 0 0 12020634 8648598 4214232 4272000 312830 756160 19260 248980 16566956 13925738 5530100 3514100 0 0 4043590 4017428 0 0 1856511 4381905 5898277 13955595 13429805 2611361 495933 41061805 42834039 10723212 10073192 30338593 32760847 X The Lymphoma Research Foundation's mission is to realize the promise of science to eradicate lymphoma and serve the community touched by this disease. By bringing together the promise of science and the power of people, a future without lymphoma is within our reach. The Foundation is committed to funding the most promising lymphoma researchers and advancing the understanding of the more than 100 different subtypes of lymphoma. LRF's disease-specificity and hyper-focus on finding cures for every type of lymphoma ensure the next generation of cancer researchers dedicate their careers to studying lymphoma, and world-leading lymphoma experts collaborate and accelerate the pace of scientific discovery. The Foundation also offers a wide range of support services, educational programs, and free publications for people with lymphoma and their care partners. The Foundation invests millions of dollars annually in its mission, all made possible by donations from its supporters. The Foundation is false false 4474748 3470000 0 RESEARCH AND SCIENTIFIC PROGRAMS - The Lymphoma Research Foundation's research program is guided by its elite Scientific Advisory Board, comprised of 45 expert lymphoma clinicians and scientists from across North America. The Foundation funds research investigating every lymphoma subtype and remains committed to supporting early career scientists to ensure the best and brightest science minds are dedicated to researching lymphoma. In addition to directly funding research grants, the Foundation facilitates collaboration and partnerships among academic scientists, clinicians, industry, regulatory agencies, and patients. Through its global lymphoma consortia and scientific workshops, the Foundation mobilizes the research community to overcome systemic challenges and speed the progress of the development of new treatments and understanding of the various subtypes of lymphoma. 4131044 44100 4272000 EDUCATIONAL PROGRAMS AND SUPPORT SERVICES - The Lymphoma Research Foundation offers a wide range of educational programs and support services for lymphoma patients and their loved ones, including in-person and virtual education programs, education publications, and a first of its kind mobile app. The Foundation Helpline provides lymphoma patients and their loved ones with individualized support and answer any lymphoma-related questions. The Foundation also offers a wide range of lymphoma-focused educational activities designed to increase the knowledge, skills and performance of healthcare professionals and to maximize the quality of care for lymphoma patients. 1096456 0 0 COMMUNITY OUTREACH AND ADVOCACY - The Lymphoma Research Foundation's focus includes community-based, patient-centered education and communications/ outreach; increasing diversity in clinical trials; and representation in lymphoma research and clinical care to achieve health equity. The Foundation is committed to advocating on behalf of the entire lymphoma community in support of this mission, working collaboratively with policymakers, regulators, the medical community, patient advocates and other stakeholders to advance efforts that will improve the lives of people with lymphoma. The Foundation supports measures which will increase federal funding for lymphoma research and ensure patient access to high quality cancer care and improved anti-cancer treatments. 9702248 true true false true false false false false false true false false false true true true false false false true false true false true false false false true true false false false false false false false false true false false false false false false false false true 29 0 true 36 true false false false false false true true false false false false false false X 18 18 false false false false false false false true true false false true true true true true true true false false AL AR CA FL GA HI IL KS KY MD MA MI MN MS NV NH NJ NM NY NC OR PA RI SC TN VA WV WI X X X THE ORGANIZATION 2123492910 WALL ST PLAZA 88 PINE STE 2400 NEW YORK NY 10005 X MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 35.0 0.0 X 329934 0 11685 LAURA WALLENSTEIN CHIEF PHILANTHROPY OFFICER 35.0 0.0 X 231590 0 22857 CAROLINA FLORES THRU 52023 SENIOR DIRECTOR OF FINANCE 35.0 0.0 X 206459 0 15553 SARAH QUINLAN CHIEF PROGRAM OFFICER 35.0 0.0 X 190287 0 21717 VICTOR GONZALEZ SENIOR DIRECTOR, PATIENT PRG. 35.0 0.0 X 151304 0 19342 MICAH BANNER SENIOR DIRECTOR, IND. GIVING 35.0 0.0 X 156834 0 8849 NICHOLAS GUERCIO SNR DIR. OF MARKETING & COMM 35.0 0.0 X 145500 0 11286 RACHEL ELMORE THRU 1112024 ASSOC. DIR OR AUDIENCE ANAL 35.0 0.0 X 103187 0 16686 EVA MIGLIORE ASSOC DIR OF SCI & PROF PROG 35.0 0.0 X 113046 0 5772 STEVEN EICHBERG BOARD CHAIR 2.0 0.0 X X 0 0 0 JEFF BLOCK VICE CHAIR AND TREASURER 2.0 0.0 X X 0 0 0 KIM METCALF VICE CHAIR 2.0 0.0 X X 0 0 0 LEIGH OLSON SECRETARY 2.0 0.0 X X 0 0 0 MICHAEL FROY BOARD MEMBER 1.0 0.0 X 0 0 0 HARRIET GREENBERG BOARD MEMBER 1.0 0.0 X 0 0 0 ROBERT MCCAULEY BOARD MEMBER 1.0 0.0 X 0 0 0 JOHN A NELSON BOARD MEMBER 1.0 0.0 X 0 0 0 SCOTT PANSKY BOARD MEMBER 1.0 0.0 X 0 0 0 DIANE PARKS BOARD MEMBER (THRU 7/2023) 1.0 0.0 X 0 0 0 JOEL POLLICK BOARD MEMBER 1.0 0.0 X 0 0 0 KEVIN SHEA BOARD MEMBER 1.0 0.0 X 0 0 0 JOHN P LEONARD MD PAST CHAIR, SCIENTIFIC ADVISOR 1.0 0.0 X 0 0 0 STEVEN J PRINCE PAST CHAIR, BOARD MEMBER 1.0 0.0 X 0 0 0 MICHAEL WERNER PAST CHAIR, BOARD MEMBER 1.0 0.0 X 0 0 0 ANN LACASCE MD MMSC BOARD MEMBER (EFF. 7/2023) 1.0 0.0 X 0 0 0 LAURENCE DOBOSH BOARD MEMBER (EFF. 3/2024) 1.0 0.0 X 0 0 0 LINDSAY SPRINGER BOARD MEMBER (EFF. 9/2023) 1.0 0.0 X 0 0 0 RAMESH SUBRAHMANIAN BOARD MEMBER (EFF. 7/2023) 1.0 0.0 X 0 0 0 Paul Belanger CONTRACTED CFO (THRU 12/2023) 35.0 0.0 X 0 0 0 1628141 0 133747 10 true true false CAREY CO 658 PECONIC AVENUE WEST BABYLON NY 11704 ACCTG & EXEC MGMT 342400 ALLISON PARTNERS LLC ONE WORLD TRADE CENTER 69TH FLOOR NEW YORK NY 10007 PR AND MEDIA 282013 Build Consulting LLC PO Box 223444 CHANTILLY VA 201533444 IT ConsultinG 245454 MED COMMUNICATIONS INC 5100 POPLAR AVENUE STE 450 MEMPHIS TN 38137 MEDICAL AFFAIRS 192090 BLACKBAUD INC PO BOX 830413 PHILADELPHIA PA 19182 SOFTWARE DEV'T 186136 9 2186116 6462482 235213 8648598 EDUCATION PROGRAMS & PATIENT SERVICES 812900 4272000 4272000 4272000 844153 844153 0 21460 21460 0 0 0 116035363 116123356 -87993 -87993 -87993 354933 2168616 354933 0 0 0 0 0 0 MISCELLANEOUS REVENUE 900099 227520 0 227520 227520 13925738 4272000 0 1005140 X 0 3289100 3289100 225000 225000 0 855075 502167 52994 299914 0 2476779 1451464 146965 878350 80461 48602 7836 24023 275477 166400 26828 82249 329636 199114 32102 98420 0 27451 27451 76140 76140 0 0 0 1943792 1038478 818112 87202 582420 537774 9657 34989 565652 346914 86106 132632 64266 12511 51372 383 0 434572 258287 101941 74344 383083 328171 9723 45189 0 1488177 1350939 67543 69695 0 0 26507 15109 11398 63613 38582 25031 GRANT REFUND -230996 -230996 DUES AND SUBSCRIPTIONS 384710 124526 234441 25743 PROCESSING FEES 70597 70 70527 LICENSES AND PERMITS 13507 36 10093 3378 4786 4786 13429805 9702248 1871046 1856511 12237893 5283497 23767395 7240023 3222919 1451760 0 0 0 0 0 0 0 0 0 0 276411 365437 195658 162175 59990 33483 0 27312260 0 0 0 0 0 0 1497197 1147579 41061805 42834039 490081 720112 8551640 7969260 125000 191090 0 0 0 0 0 0 0 0 0 0 1556491 1192730 10723212 10073192 X 4979089 7993253 25359504 24767594 30338593 32760847 41061805 42834039 495933 1926321 X false true X true false X 9778478 10361473 9913811 12020634 12920598 54994994 0 0 9778478 10361473 9913811 12020634 12920598 54994994 17098892 37896102 312354 234178 176115 322661 865613 1910921 0 2356 39700 22100 9384 227520 301060 57206975 0.66244 0.66114 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false true 30000 false true 59619 89619 false SCHEDULE C, PART II-B, LINE 1: CONTACT WITH LEGISLATORS, THEIR STAFF, GOVERNMENT OFFICIALS, LEGISLATIVE BODIES, AND ASSOCIATED GRASSROOTS ACTIVITIES TO PRESENT ISSUES OF CONCERN RELATED TO LYMPHOMA. 113640 81921 31719 61685 61685 0 20333 18569 1764 33483 0 OPERATING LEASE LIABILITY 1192730 1192730 X 17119034 1926321 1266975 3193296 13925738 13925738 14696780 1266975 1266975 13429805 13429805 SCHEDULE D, PART X, LINE 2: The Foundation follows GAAP, which requires accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and measurement. GAAP provides that the tax effects from an uncertain tax position can only be recognized in the financial statements if the position is "more likely than not" to be sustained if the position were to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged. The Foundation is incorporated in the state of California and is exempt from federal income tax under IRC Section 501(c)(3), though it is subject to tax on income unrelated to its exempt purpose, unless that income is otherwise excluded by the IRC. The Organization has no unrelated income associated with its exempt purpose. The Foundation has processes presently in place to ensure the maintenance of its tax-exempt status, to identify and report unrelated income, to determine its filing and tax obligations in jurisdictions for which nexus was established, and to identify and evaluate other matters that may be considered tax positions. The Foundation has determined that there are no material uncertain tax positions that require recognition or disclosure in the financial statements. As of JUNE 30, 2024, the Foundation was not subject to an examination by a taxing authority. true North America 0 0 Grantmaking NONE 225000 0 0 0 0 225000 225000 RESEARCH GRANT North America 1 225000 WIRE FMV false false false false false false ANNUAL GALA 1187476 968050 219426 219426 SOUTH FL GOLF 332256 253505 78751 78751 0 1021317 964561 56756 56756 2541049 2186116 354933 354933 354933 true RESEARCH GRANT 26 3245000 FMV PATIENT AID GRANT 441 44100 FMV PART I, LINE 2: THE FOUNDATION EXPERT SCIENTIFIC ADVISORY BOARD (SAB) CONDUCTS PEER REVIEW FOR ALL GRANT PROPOSALS AND RECOMMENDS THE HIGHEST-SCORING PROPOSALS TO THE FOUNDATION BOARD OF DIRECTORS FOR FUNDING. THE BOARD OF DIRECTORS THEN CONSIDERS AND APPROVES THE GRANTS WHICH ARE TO BE FUNDED. ONCE A GRANT IS APPROVED AND ACCEPTED BY THE GRANTEE, THE GRANTEE WILL BEGIN TO RECEIVE INSTALLMENTS BASED UPON THE PAYMENT SCHEDULE AS DICTATED IN THE GRANT CONTRACT. THE SAB AND LRF'S RESEARCH DEPARTMENT ANNUALLY REVIEW EACH GRANTEE'S PROGRESS AGAINST DELIVERABLES AND APPROVES THE CONTINUATION OF GRANT PAYMENTS. PART III, LINE 2: THE FOUNDATION PROVIDES FINANCIAL ASSISTANCE TO LYMPHOMA PATIENTS WHO STRUGGLE TO PAY FOR EXPENSES RELATED TO THEIR LYMPHOMA TREATMENTS, SUCH AS MEDICAL BILLS AND TRANSPORTATION COSTS. THE FOUNDATION SUPPORT SERVICES STAFF REVIEWS THE APPLICATIONS, VALIDATES APPLICATION CRITERIA AND SUBMITS APPLICATIONS FOR PAYMENT APPROVAL TO DEPARTMENT LEADERSHIP. X X X true false false false false false false true false MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 299934 0 30000 0 0 0 11671 0 14 0 341619 0 0 0 CAROLINA FLORES THRU 52023 SENIOR DIRECTOR OF FINANCE 74540 0 0 0 131919 0 3298 0 12255 0 222012 0 0 0 SARAH QUINLAN CHIEF PROGRAM OFFICER 190287 0 0 0 0 0 9514 0 12203 0 212004 0 0 0 MICAH BANNER SENIOR DIRECTOR, IND. GIVING 156834 0 0 0 0 0 7842 0 1007 0 165683 0 0 0 VICTOR GONZALEZ SENIOR DIRECTOR, PATIENT PRG. 151304 0 0 0 0 0 7565 0 11777 0 170646 0 0 0 NICHOLAS GUERCIO SNR DIR. OF MARKETING & COMM 145500 0 0 0 0 0 0 0 11286 0 156786 0 0 0 LAURA WALLENSTEIN CHIEF PHILANTHROPY OFFICER 221590 0 10000 0 0 0 11080 0 11777 0 254447 0 0 0 PART I, LINE 4A: SCHEDULE J, PART II, COLUMN B(III) REPORTS SEVERANCE PAYMENT OF $131,919 FOR CAROLINA FLORES. PART I, LINE 7: SCHEDULE J, PART II, COLUMN (B)(II) REPORTS DISCRETIONARY INCENTIVE AMOUNTS THAT WERE APPROVED BY THE BOARD BASED UPON PERFORMANCE. X 14 235213 MARKET QUOTATION false true false SCHEDULE M, PART I, COLUMN B: NUMERICAL DATA HERE REPRESENTS THE TOTAL NUMBER OF CONTRIBUTIONS RECEIVED. FORM 990, PART VI, SECTION B, LINE 11B: FORM 990 WAS PREPARED BY A NATIONAL ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. THE FORM 990 WAS REVIEWED IN DETAIL BY MANAGEMENT. AFTER REVIEW A FINAL DRAFT WAS PRESENTED TO THE AUDIT COMMITTEE AND FULL BOARD OF DIRECTORS FOR REVIEW AND COMMENT PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C: THE CONFLICT OF INTEREST POLICY IS REVIEWED AND SIGNED ANNUALLY BY BOARD MEMBERS, OFFICERS AND STAFF. FORM 990, PART VI, SECTION B, LINE 15A: THE ORGANIZATION SETS COMPENSATION IN A MANNER GIVING RISE TO A REBUTTABLE PRESUMPTION THAT THE COMPENSATION IS REASONABLE UNDER STANDARDS SET FORTH IN TREASURY REGULATIONS SECTION 53.4958-6. SALARIES OF THE SENIOR STAFF, INCLUDING THE CEO, ARE DETERMINED BASED UPON MARKET INFORMATION COMPARABLE TO THE POSITION IN OTHER NON-PROFIT ORGANIZATIONS. THE CEO'S COMPENSATION IS APPROVED BY THE EXECUTIVE COMMITTEE (EC), WHICH HAS BEEN DULY AUTHORIZED BY THE BOARD AND CONSISTS OF INDEPENDENT MEMBERS, AND THE APPROVAL IS DOCUMENTED CONTEMPORANEOUSLY IN THE EC MINUTES. FORM 990, PART VI, SECTION C, LINE 19: THE ORGANIZATION'S GOVERNING DOCUMENTS, FINANCIAL STATEMENTS AND THE CONFLICT OF INTEREST POLICY ARE AVAILABLE TO THE PUBLIC UPON REQUEST. THE ORGANIZATION ALSO MAKES ITS FINANCIAL STATEMENTS AVAILABLE THEIR WEBSITE. FORM 990 PART IX LINE 11G DESCRIPTION:CONSULTANT FEES TOTAL FEES:1943792